Tens of thousands of hospital patients were put at risk when Medtronic unlawfully supplied a bone grafting kit to hospitals that was not registered on the Australian Register of Therapeutic Goods, according to new regulatory proceedings.
BlueScope has labelled “delusional” an argument by the competition regulator that alleged correspondence from a distributor about the steel company’s suggested higher prices was evidence of price-fixing.
Steel maker Bluescope’s claim that it didn’t engage in cartel conduct because it only encouraged distributors to set a price for its products would “eviscerate” cartel laws, the ACCC has told a court.
The Commissioner of Patents has appealed a landmark judgment that found artificial intelligence can be named an inventor on a patent application.
National Australia Bank has been hit with a $18.5 million fine after admitting to allegations by ASIC that it failed to adequately disclose its adviser fees for five years.
The Commonwealth is currently facing 83 negligence lawsuits in the Federal Court by asylum seekers who claim the government knew they were vulnerable to physical and psychological injuries and other illnesses, which could be exacerbated by detention in prison-like facilities.
With mediation failing to resolve an expansive class action against the federal government over its use of allegedly toxic firefighting foam, a judge has charted a plan to avoid a “Brobdingnagian” trial and efficiently determine the claims of group members around eight military bases across Australia.
Auctus Resources will not be able to hang on to a $2.3 million R&D tax offset refund which the Full Court found was paid by mistake, after the High Court turned down its special leave application.
A judge has found collapsed education provider Phoenix Institute acted unconscionably and with “callous indifference” by enticing vulnerable consumers to enrol in unsuitable courses with promises of free laptops.
The Federal Court has dealt US drug giant Merck Sharp & Dohme a devastating blow, overturning an “untenable” patent term extension which would have protected the monopoly of its multibillion-dollar Januvia and Janumet diabetes drugs beyond July 2o22.